Apremilast in the Treatment of Central Centrifugal Cicatricial Alopecia: An Open-Label Pilot Study
Journal of Drugs in Dermatology · 2025
DOI: 10.36849/jdd.8962 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Drugs in Dermatology, 2025. Verfasst von Ahuva Cices und 6 weiteren Autor:innen. Hauptthemen laut MEDLINE: Thalidomide, Alopecia, Anti-Inflammatory Agents, Non-Steroidal, Cicatrix.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Cices, A., El-Kashlan, N., Kaufman, B., Rosa, J. C. D., Sanabria-Gonzalez, I., Khattri, S., & Alexis, A. (2025). Apremilast in the Treatment of Central Centrifugal Cicatricial Alopecia: An Open-Label Pilot Study. Journal of Drugs in Dermatology. https://doi.org/10.36849/jdd.8962
Vancouver
Cices A, El-Kashlan N, Kaufman B, Rosa JCD, Sanabria-Gonzalez I, Khattri S, et al. Apremilast in the Treatment of Central Centrifugal Cicatricial Alopecia: An Open-Label Pilot Study. Journal of Drugs in Dermatology. 2025. doi:10.36849/jdd.8962
BibTeX
@article{Cices2025,
author = {Cices, Ahuva and El-Kashlan, Nour and Kaufman, Bridget and Rosa, Joel Correa Da and Sanabria-Gonzalez, Ingrid and Khattri, Saakshi and Alexis, Andrew},
title = {Apremilast in the Treatment of Central Centrifugal Cicatricial Alopecia: An Open-Label Pilot Study},
journal = {Journal of Drugs in Dermatology},
year = {2025},
doi = {10.36849/jdd.8962}
}
EUVIMED